Investors Purchase Large Volume of Call Options on Biohaven (NYSE:BHVN)

Posted by on Jun 17th, 2026

Biohaven Ltd. (NYSE:BHVN – Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 15,269 call options on the company. This is an increase of approximately 956% compared to the average daily volume of 1,446 call options.

Biohaven Price Performance

Shares of Biohaven stock traded up $1.55 during trading hours on Wednesday, reaching $13.64. The company’s stock had a trading volume of 4,316,115 shares, compared to its average volume of 2,517,689. The firm has a 50 day moving average price of $10.09 and a 200-day moving average price of $10.55. Biohaven has a one year low of $7.48 and a one year high of $18.57. The company has a debt-to-equity ratio of 1.87, a current ratio of 7.41 and a quick ratio of 7.41. The stock has a market cap of $2.05 billion, a P/E ratio of -2.40 and a beta of 1.35.

Biohaven (NYSE:BHVN – Get Free Report) last posted its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, analysts predict that Biohaven will post -3.07 EPS for the current year.

Hedge Funds Weigh In On Biohaven

Several hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after acquiring an additional 16,127,247 shares during the period. Suvretta Capital Management LLC boosted its holdings in Biohaven by 83.0% during the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock valued at $116,140,000 after acquiring an additional 4,666,666 shares during the period. Infinitum Asset Management LLC grew its stake in Biohaven by 267.6% in the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after acquiring an additional 4,550,000 shares in the last quarter. Stifel Financial Corp grew its stake in Biohaven by 50.3% in the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock worth $112,221,000 after acquiring an additional 3,328,506 shares in the last quarter. Finally, Stempoint Capital LP bought a new position in Biohaven in the 1st quarter worth about $13,489,000. 88.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BHVN has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $10.00 target price on shares of Biohaven in a report on Tuesday, May 26th. Royal Bank Of Canada dropped their target price on shares of Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a report on Wednesday, May 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. Finally, Wall Street Zen downgraded shares of Biohaven from a “sell” rating to a “strong sell” rating in a report on Sunday, April 26th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.27.

Read Our Latest Stock Analysis on Biohaven

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.

Featured Stories

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.